These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 26824186

  • 1. miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells.
    Gomes SE, Simões AE, Pereira DM, Castro RE, Rodrigues CM, Borralho PM.
    Oncotarget; 2016 Feb 23; 7(8):9368-87. PubMed ID: 26824186
    [Abstract] [Full Text] [Related]

  • 2. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, Okabayashi K, Tsuruta M, Hasegawa H, Kitagawa Y.
    Oncol Rep; 2014 May 23; 31(5):2115-22. PubMed ID: 24626880
    [Abstract] [Full Text] [Related]

  • 3. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F.
    Int J Cancer; 2014 May 01; 134(9):2146-55. PubMed ID: 24136682
    [Abstract] [Full Text] [Related]

  • 4. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
    Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Morales SB, González M, Mordoh J, Bianchini M.
    Innate Immun; 2009 Apr 01; 15(2):91-100. PubMed ID: 19318419
    [Abstract] [Full Text] [Related]

  • 5. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S, Bäumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Müller-Tidow C.
    Clin Cancer Res; 2015 Mar 15; 21(6):1383-94. PubMed ID: 25589625
    [Abstract] [Full Text] [Related]

  • 6. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
    Trotta AM, Ottaiano A, Romano C, Nasti G, Nappi A, De Divitiis C, Napolitano M, Zanotta S, Casaretti R, D'Alterio C, Avallone A, Califano D, Iaffaioli RV, Scala S.
    Cancer Immunol Res; 2016 Apr 15; 4(4):366-74. PubMed ID: 26817995
    [Abstract] [Full Text] [Related]

  • 7. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH, Leung WH, Pang YJ, Hsu HH.
    Oncol Rep; 2016 Jan 15; 35(1):107-16. PubMed ID: 26496897
    [Abstract] [Full Text] [Related]

  • 8. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.
    Evans MK, Sauer SJ, Nath S, Robinson TJ, Morse MA, Devi GR.
    Cell Death Dis; 2016 Jan 28; 7(1):e2073. PubMed ID: 26821068
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
    Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Abbruzzese A, Tagliaferri P, Caraglia M.
    Eur J Cancer; 2010 Jun 28; 46(9):1703-11. PubMed ID: 20399639
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E.
    Clin Cancer Res; 2007 Mar 01; 13(5):1552-61. PubMed ID: 17332301
    [Abstract] [Full Text] [Related]

  • 13. MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1.
    Mussnich P, Rosa R, Bianco R, Fusco A, D'Angelo D.
    Expert Opin Ther Targets; 2015 Mar 01; 19(8):1017-26. PubMed ID: 26107137
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 17. Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity.
    Nakamura H, Tamaki S, Yagyuu T, Yamakawa N, Hatake K, Kirita T.
    Anticancer Res; 2019 Mar 20; 39(3):1275-1282. PubMed ID: 30842158
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.